

# CERTIFICATE OF ANALYSIS No.: 2024-13919

## CLIENT

Tenacious Halfway Limited, 11 Shepherd Market  
W1J 7PG London, United Kingdom

## SAMPLE \*

Provacan CBD Balm 900mg / 3%











Sample condition: SUITABLE  
Sample ID: 2405014  
Sample type: Balm  
Batch No.: \* BA03024029A

Work order: 2024-109949  
Analysis ID: 2024\_042  
Method ID: PHL\_RPC\_16C  
Method SOP: MET-LAB-001-08

Sample received: 31/01/2024  
Start of analysis: 31/01/2024  
End of analysis: 02/02/2024  
Analyst: Valentina Malin

\* Information provided by the client.

CANNABINOID PROFILE	Concentration [% w/w]	Expanded uncertainty [% w/w]	Graphic presentation of relative cannabinoid concentration
<b>CBDV</b> - Cannabidivarin	< LOQ	n/a	
<b>CBDA</b> - Cannabidiolic acid	1.848	0.092	
<b>CBGA</b> - Cannabigerolic acid	0.048	0.014	
<b>CBG</b> - Cannabigerol	0.0317	0.0095	
<b>CBD</b> - Cannabidiol	1.287	0.064	
<b>THCV</b> - Tetrahydrocannabivarin	n/a	n/a	
<b>CBN</b> - Cannabinol	< LOQ	n/a	
<b>Δ<sup>9</sup>-THC</b> - Δ-9-Tetrahydrocannabinol	0.064	0.014	
<b>Δ<sup>8</sup>-THC</b> - Δ-8-Tetrahydrocannabinol	< LOQ	n/a	
<b>CBL</b> - Cannabicyclol	< LOQ	n/a	
<b>CBC</b> - Cannabichromene	0.047	0.010	
<b>Δ<sup>9</sup>-THCA</b> - Δ-9-Tetrahydrocannabinolic acid	0.0302	0.0066	
<b>CBV</b> - Cannabivarin	< LOQ	n/a	
<b>CBCA</b> - Cannabichromenic acid	0.057	0.013	
<b>CBT</b> - Cannabicitran	< LOQ	n/a	
<b>CBE</b> - Cannabielsoin	< LOQ #	n/a	

Units and abbreviations: % w/w = weight percent, < LOQ = below the limit of quantitation (0.03 % w/w), ND = not detected, n/a = not available.

The results given herein apply only to the sample as received and tested. **Expanded Uncertainty** was calculated using coverage factor  $k = 2$ , corresponding to a double standard uncertainty and characterizes the interval value in which it is possible to expect the real value with a probability of 95%. This is stated according to the ISO/IEC Guide 98-3.

Total or partial reproduction of this document is not allowed without the permit from PharmaHemp d.o.o. The document does not substitute any other legal document.

Date issued:

02/02/2024

Approved by:



mag. Janja Ahej  
Analytical Laboratory Manager

Authorized by:



dr. Boštjan Jančar  
Chief Technology Officer

End of Certificate